COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,886 Articles (22,568 medRxiv, 8,318 bioRxiv)

Most recent first Previous |  Page 951: Articles 9501-9510  | Next

T cell response following anti COVID-19 BNT162b2 vaccination is maintained against the SARS-CoV-2 Omicron B.1.1.529 variant of concern
Cohen, H., Rotem, S., Elia, U., Bilinsky, G., Levy, I., Chitlaru, T., Bar-Haim, E.
10.1101/2022.01.19.476497 — Posted: 2022-01-20
Serological screening suggests single SARS-CoV-2 spillover events to cattle
Wernike, K., Boettcher, J., Amelung, S., Albrecht, K., Gaertner, T., Donat, K., Beer, M.
10.1101/2022.01.17.476608 — Posted: 2022-01-20
High prevalence of olfactory disorders 18 months after contracting COVID-19
Tognetti, A., Thunell, E., Olsson, M. J., Greilert-Norin, N., Havervall, S., Thalin, C., Lundstrom, J. N.
10.1101/2022.01.20.22269490 — Posted: 2022-01-20
SARS-CoV-2 Omicron efficiently infects human airway, but not alveolar epithelium
Lamers, M. M., Mykytyn, A. Z., Breugem, T. I., Groen, N., Knoops, K., Schipper, D., van Acker, R., van den Doel, P. B., Bestebroer, T., Koopman, C. D., Reusken, C., Muraro, M. J., GeurtsvanKessel, C. H., van Royen, M. E., Peters, P. J., Zhang, J., Haagmans, B. L.
10.1101/2022.01.19.476898 — Posted: 2022-01-20
Inflammation in the COVID-19 airway is due to inhibition of CFTR signaling by the SARS-CoV-2 Spike protein
Caohuy, H., Eidelman, O., Chen, T., Yang, Q., Walton, N. I., Pollard, H. B.
10.1101/2022.01.18.476803 — Posted: 2022-01-20
Molecular basis of broad neutralization against SARS-CoV-2 variants including Omicron by a human antibody
Zhang, Z., Ju, B., Zheng, Q., Guo, H., Fan, Q., Li, T., Song, S., Sun, H., Shen, S., Zhou, X., Cheng, L., Xue, W., Cui, L., Zhou, B., Ge, X., Wang, H., Wang, M., Li, S., Xia, N.
10.1101/2022.01.19.476892 — Posted: 2022-01-20
NRP1 and furin as putative mediators of SARS-CoV-2 entry into human brain cells
Kumar, A., Narayan, R. K., Kumar, S., Pareek, V., Kumari, C., Jha, R. K., Prasoon, P.
10.1101/2022.01.19.476893 — Posted: 2022-01-20
SARS-CoV-2 infection results in lasting and systemic perturbations post recovery
Frere, J. J., Serafini, R. A., Pryce, K. D., Zazhytska, M., Oishi, K., Golynker, I., Panis, M., Zimering, J., Horiuchi, S., Hoagland, D. A., Moller, R., Ruiz, A., Overdevest, J. B., Kodra, A., Canoll, P. D., Goldman, J. E., Borczuk, A. C., Chandar, V., Bram, Y., Schwartz, R., Lomvardas, S., Zachariou, V., tenOever, B.
10.1101/2022.01.18.476786 — Posted: 2022-01-20
A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants
Weinstein, J. B., Bates, T. A., Leier, H. C., McBride, S. K., Barklis, E., Tafesse, F. G.
10.1101/2022.01.18.476801 — Posted: 2022-01-20
Long-Term Persistence of IgG Antibodies in recovered COVID-19 individuals at 18 months and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response
Dehgani-Mobaraki, P., Wang, C., Floridi, A., Floridi, E., Zaidi, A. K.
10.1101/2022.01.18.22269349 — Posted: 2022-01-20

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).